Axsome touts success of phase 3 trial of Sunosi in ADHD, adding to 'string of recent wins'

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome Therapeutics.

The New York City central nervous system (CNS) specialist has scored in a phase 3 trial testing Sunosi (solriamfetol) on adults with attention deficit hyperactivity disorder (ADHD).